20:02 , Dec 14, 2018 |  BC Week In Review  |  Company News

Strata to screen patients for Phase I of CBT's CBT-101

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) and Strata Oncology Inc. (Ann Arbor, Mich.) partnered to enroll patients in a Phase I trial evaluating CBT-101 to treat c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)-dysregulated malignancies....
21:39 , Nov 30, 2018 |  BC Week In Review  |  Company News

CBT, Bossan partner for combination trials

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) gained exclusive, worldwide rights to develop and commercialize EGFR inhibitor ES-072 outside of Greater China from Zhejiang Bossan Pharmaceutical Co. Ltd. (Hangzhou, China). CBT and Bossan will jointly develop and...
20:49 , Oct 13, 2017 |  BioCentury  |  Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
07:00 , Aug 30, 2016 |  BC Extra  |  Financial News

CBT raises $9.8M in series A

Cancer company CBT Pharmaceuticals Inc. (Santa Clara, Calif.) raised $9.8 million in a series A round led by OrbiMed Asia. CBT's parent company is CRO Crown Bioscience International Inc. (TPex-E:6554), which seeded the biotech with...